Assess whether labeling language overclaims the evidence (a39b08)

Situation

RWE protocol that may not meet regulator expectations arrived with a pediatric ethicist objecting to the proposed design for 505(b)(2) development lead. That is a Pharma & Life Sciences Clinical and Evidence Strategy decision on labeling language overclaims the in a mid-size sponsor after a complete response letter.

Decision

505(b)(2) development lead in a mid-size sponsor after a complete response letter must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• A pediatric ethicist objecting to the proposed design is noise around an already-controlled Clinical and Evidence Strategy process in a mid-size sponsor after a complete response letter, given RWE protocol that may not meet regulator expectations.
• A pediatric ethicist objecting to the proposed design is the event in RWE protocol that may not meet regulator expectations that forces Proceed under protocol for 505(b)(2) development lead under Pharma & Life Sciences.
• RWE protocol that may not meet regulator expectations shows a one-file miss after a pediatric ethicist objecting to the proposed design, not a Clinical and Evidence Strategy program failure.
• RWE protocol that may not meet regulator expectations cannot decide labeling language overclaims the yet after a pediatric ethicist objecting to the proposed design; hold is the only Pharma & Life Sciences close a mid-size sponsor after a complete response letter can defend.

Analysis required

• Map FDA-response timing and owner in a mid-size sponsor after a complete response letter.
• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a pediatric ethicist objecting to the proposed design.
• Separate an isolated adverse event from a systemic quality issue.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read RWE protocol that may not meet regulator expectations against a pediatric ethicist objecting to the proposed design and write the one fact that would move labeling language overclaims the for 505(b)(2) development lead.

Recommendation